Marianna Rowlands Email & Phone Number

Cambridge, Ma, Us

Basel, Baselstadt, Ch

- Leading the biomarker strategies for B-cell modulating/depleting assets and a team of biomarker & data scientists dedicated to advancing programs across Autoimmune indications and stages of clinical development- Leading the translational & biomarker strategy and implementation to data generation for all Novartis Inflammasome assets and associated portfolio across Gen Med Therapeutic Areas

Basel, Baselstadt, Ch

- Leading the translational & biomarker strategy for all NVS Inflammasome assets and associated portfolio across Gen Med Therapeutic Areas, having enabled: first patient selection strategy for an inflammasome asset, novel PD signatures to allow differentiation, key decision-making biomarker data to allow indication prioritization, cross-fertilization of learnings with oversight across over 10 clinical studies.- Lead author and presenter of first external dissemination of key clinical and biomarker data for one of the inflammasome assets, MAS825, as oral presentation at FOCIS 2022

Basel, Baselstadt, Ch

- Head of laboratory and research team with expertise in the development of innovative multi-modality biomarkers and generation of clinical study data to address key scientific questions, provide PD/MoA insights into clinical assets and generate hypotheses around responder populations- Rising Star 2021 Novartis Translational Medicine End of year Award recipient

Waltham, Ma, Us

Developed and implemented correlative clinical biomarker strategy for the company’s first Immuno-Oncology clinical candidate in collaboration with teams at MD Anderson Cancer Center

Cambridge, Ma, Us

• Leader of research team focusing on myeloid targets and cellular metabolism-mediated immune suppression and resistance to Immunotherapies• Led assay and model infrastructure development to study myeloid cell targets. Progressed early drug discovery projects to go, no-go decisions by directing teams to generate key preclinical data to test therapeutic hypotheses

Basel, Baselstadt, Ch

• Led and progressed drug discovery projects from discovery to IND filing and early clinical stages as Project team lead/ Biology lead• Led biomarker discovery research that resulted in the identification of novel candidate biomarkers for clinical trial exploratory endpoints and to a patent inventorship

Basel, Baselstadt, Ch

Laboratory head of a team of in vitro biologists developing complex in vitro and ex vivo pharmacology cellular models of immune function for drug candidate MoA characterization and target discovery

Gaithersburg, Maryland, Us

Identified, validated and progressed new myeloid/ Immunology targets and biologics drug candidates across the Immuno-Oncology pipeline

Ithaca, Ny, Us

• Awarded a UK-US Fulbright Cancer Research Fellowship • Identified the Inhibitor of Differentiation-1 (Id1) as a novel target for the impairment of myeloid differentiation and anti-tumor immune responses during tumor progression

Oxford, Oxfordshire, Gb

• Awarded a British Heart Foundation Junior Research Fellowship• Identified Galectin-3 as a novel macrophage derived amplifier of atherosclerotic plaque inflammation and a candidate biomarker of plaque instability

Hinxton, Cambridgeshire, Gb

Participated in the generation of the first linkage disequilibrium map - human chromosome 22

Phd, Molecular & Cellular Biology

Bsc Hons, Biochemistry